This federal contract award, SPE2DP16D0008|0021, was made by the Medical Supply Chain division of the Defense agency to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $101,188.26 firm-fixed-price delivery order is for the antiviral medication oseltamivir phosphate, with a performance period ending on September 22, 2017. The award is not associated with a set-aside program. Genentech USA, Inc. is a major supplier of pharmaceuticals and biologics to federal agencies, holding various contract vehicles including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs and a $27.9 million indefinite delivery contract with the Defense Logistics Agency. This delivery order supports the Defense agency's requirements for medical supplies and pharmaceuticals.